Fisetin Senolytic Cycling: Monthly vs Quarterly Dosing Schedules
Expert Summary
No head-to-head human trial has directly compared monthly vs quarterly fisetin senolytic cycling. Based on senescent cell reaccumulation kinetics from animal studies (approximately 30% recovery within 4 weeks of clearance in aged mice), monthly cycling may be superior for maintaining a low senescent cell burden, while quarterly dosing may be sufficient for prevention in younger individuals.
Key Facts
- Reaccumulation rate: After effective senolytic treatment, senescent cells begin reaccumulating within days in aged organisms. Studies suggest 50% of cleared cells are replaced within 6–8 weeks in old mice.
- Monthly protocol: 2 consecutive days at 20 mg/kg per month. This maintains lower steady-state senescent cell burden. More appropriate for individuals over 55 or with high inflammatory burden.
- Quarterly protocol: 2 consecutive days at 20 mg/kg every 3 months. Simpler to adhere to; may be sufficient for prevention in individuals under 50 with low baseline inflammation.
- Annual cumulative dose: Monthly protocol delivers ~24 days of fisetin/year vs 8 days/year for quarterly. The increased dose appears safe based on safety data from continuous low-dose use.
- Age-based guidance: Under 45: quarterly or less frequent. Ages 45–60: bimonthly to monthly. Over 60: monthly, potentially with additional quercetin on off-months.
- Scheduling tip: Tie senolytic days to a fixed calendar marker (first weekend of each month). Consistency in scheduling reduces missed sessions.
Recommended Products
Frequently Asked Questions
How do I know if I need monthly vs quarterly cycling?
Higher-frequency cycling is favored if you have chronic inflammation markers (elevated CRP, IL-6), are over 55, have metabolic syndrome, or have experienced significant cellular stress (illness, radiation, chemotherapy).
Can I track senolytic effectiveness at home?
High-sensitivity CRP, ferritin, and IL-6 (via extended labs) can serve as indirect proxies for SASP-driven inflammation. Improvements in these markers after cycling sessions suggest effective senolytic activity.
Is more frequent senolytic use better?
Not necessarily. Excessive senolysis may impair tissue repair, as some senescent cells play beneficial roles in wound healing. The evidence supports periodic rather than continuous senolytic use.
Scientific References
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020. PMID: 32686219
- Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011. PMID: 22048312